Afatinib dimaleate
| Title | Journal |
|---|---|
| YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. | PloS one 20170101 |
| Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. | The Lancet. Oncology 20150901 |
| Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. | Nature reviews. Clinical oncology 20131001 |
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. | The Journal of pharmacology and experimental therapeutics 20121101 |
| Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. | Molecular cancer therapeutics 20121001 |
| Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. | Critical reviews in oncology/hematology 20120901 |
| Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET. | Lung cancer (Amsterdam, Netherlands) 20120901 |
| New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? | Cancer treatment reviews 20120801 |
| A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. | Breast cancer research and treatment 20120801 |
| Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. | International journal of oncology 20120601 |
| A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. | Breast cancer research and treatment 20120601 |
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. | The Lancet. Oncology 20120501 |
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. | The Lancet. Oncology 20120501 |
| Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). | Cancer chemotherapy and pharmacology 20120401 |
| Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. | Cancer chemotherapy and pharmacology 20120401 |
| Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. | Lung cancer (Amsterdam, Netherlands) 20120401 |
| EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. | Molecular cancer therapeutics 20120301 |
| Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. | BMC medicine 20120101 |
| Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. | British journal of cancer 20111108 |
| EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111015 |
| Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. | International journal of oncology 20110801 |
| Afatinib (BIBW 2992) development in non-small-cell lung cancer. | Future oncology (London, England) 20110701 |
| The search for improved systemic therapy of non-small cell lung cancer--what are today's options? | Lung cancer (Amsterdam, Netherlands) 20110601 |
| Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. | Anticancer research 20110601 |
| The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. | Expert review of anticancer therapy 20110501 |
| BIBW 2992 in non-small cell lung cancer. | Expert opinion on investigational drugs 20110301 |
| EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. | Targeted oncology 20101201 |
| New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. | Expert opinion on investigational drugs 20101201 |
| Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100901 |
| Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. | Molecular cancer therapeutics 20100601 |
| The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. | Cancer investigation 20100501 |
| Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. | Cancer research 20100201 |
| Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. | Cancer treatment reviews 20091201 |
| Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. | The Journal of clinical investigation 20091001 |
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. | Clinical lung cancer 20090701 |
| BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. | Current opinion in investigational drugs (London, England : 2000) 20081201 |
| Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081115 |
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. | Oncogene 20080807 |
| A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. | British journal of cancer 20080115 |